Such pathways included histone modification with arginine deiminase activity, serine-type hydrolase activity, and TGF-β signaling (Supplementary Table S5); all of which were previously associated with AD [34, 35] or have been suggested as potential pharmacologic targets [36]. Here, TGFB1 is linked to Alzheimer disease.